Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
Australian Market

Neuroscientific Biopharmaceuticals Ltd. (NSB) Income Statement


Neuroscientific Biopharmaceuticals Ltd. Income Statement

Last quarter (Q4 2022), Neuroscientific Biopharmaceuticals Ltd.'s total revenue was AU$―, a decrease of ― from previous quarter. In Q4, Neuroscientific Biopharmaceuticals Ltd.'s net income was AU$―. See Neuroscientific Biopharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 22Jun 21Jun 20Jun 19
Total Revenue
Cost of Revenue
Gross Profit
Operating Expense
-AU$ 10.50MAU$ 4.22MAU$ 2.94MAU$ 1.78M
Operating Income
-AU$ -10.50MAU$ -4.22MAU$ -2.94MAU$ -1.78M
Net Non Operating Interest Income Expense
-AU$ 68.45KAU$ 27.58KAU$ 32.32KAU$ 85.44K
Other Income Expense
--AU$ 1.02MAU$ 40.54KAU$ 33.85K
Pretax Income
-AU$ -10.44MAU$ -3.18MAU$ -2.87MAU$ -1.66M
Tax Provision
-AU$ 0.00AU$ 0.00AU$ 0.00AU$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
-AU$ -10.44MAU$ -3.18MAU$ -2.87MAU$ -1.66M
Basic EPS
-AU$ -0.07AU$ -0.02AU$ -0.04AU$ -0.02
Diluted EPS
-AU$ -0.07AU$ -0.02AU$ -0.04AU$ -0.02
Basic Average Shares
-AU$ 143.47MAU$ 143.47MAU$ 78.38MAU$ 71.53M
Diluted Average Shares
-AU$ 143.47MAU$ 143.47MAU$ 78.38MAU$ 71.53M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
Net Income From Continuing And Discontinued Operation
-AU$ -10.44MAU$ -3.18MAU$ -2.87MAU$ -1.66M
Normalized Income
-AU$ -10.44MAU$ -3.18MAU$ -2.87MAU$ -1.66M
Interest Expense
--AU$ 63.00AU$ 3.42K-
-AU$ -10.50MAU$ -3.18MAU$ -2.87MAU$ -1.78M
-AU$ -10.44MAU$ -3.12MAU$ -2.81MAU$ -1.72M
Currency in AUD

Neuroscientific Biopharmaceuticals Ltd. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis